Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stéphane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P; Intergroupe Français des Leucémies Myéloïdes Chronique; Group for Research in Adult Acute Lymphoblastic Leukemia. Rea D, et al. Among authors: huguet f. Leukemia. 2006 Mar;20(3):400-3. doi: 10.1038/sj.leu.2404115. Leukemia. 2006. PMID: 16437142
t(9;11)(p22;q23) translocation in blastic phase of chronic myeloid leukemia.
Dastugue N, Duchayne E, Huguet F, Demur C, Plaisancie H, Calvas P, Bourrouillou G, Pris J, Colombies P. Dastugue N, et al. Among authors: huguet f. Cancer Genet Cytogenet. 1992 Oct 1;63(1):37-42. doi: 10.1016/0165-4608(92)90061-c. Cancer Genet Cytogenet. 1992. PMID: 1423224
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Fabères C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P. Reiffers J, et al. Among authors: huguet f. Leukemia. 1996 Mar;10(3):389-95. Leukemia. 1996. PMID: 8642852 Clinical Trial.
Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.
Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, Huguet F, Corront B, Cony-Makhoul P, Gastaut JA, Laurent G, Molina L, Broustet A, Maraninchi D, Pris J, Hollard D, Faberes C. Reiffers J, et al. Among authors: huguet f. Leukemia. 1996 Dec;10(12):1874-82. Leukemia. 1996. PMID: 8946925 Clinical Trial.
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
Blaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C, Molina L, Nedellec G, Vernant JP, Legros M, Gabus R, Huguet F, Brandely M, Hercend T, Olive D, Maraninchi D. Blaise D, et al. Among authors: huguet f. Leuk Lymphoma. 1997 May;25(5-6):469-78. doi: 10.3109/10428199709039034. Leuk Lymphoma. 1997. PMID: 9250817 Clinical Trial.
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. Fenaux P, et al. Among authors: huguet f. Blood. 1999 Aug 15;94(4):1192-200. Blood. 1999. PMID: 10438706 Free article. Clinical Trial.
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N, Maloisel F, Cahn JY, Reman O, Gratecos N, Berthou C, Huguet F, Kotoucek P, Travade P, Buzyn A, de Revel T, Vilque JP, Naccache P, Chomienne C, Degos L, Fenaux P. Thomas X, et al. Among authors: huguet f. Leukemia. 2000 Jun;14(6):1006-13. doi: 10.1038/sj.leu.2401800. Leukemia. 2000. PMID: 10865965
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.
De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, Bordessoule D, San Miguel J, Link H, Desablens B, Stamatoullas A, Deconinck E, Geiser K, Hess U, Maloisel F, Castaigne S, Preudhomme C, Chomienne C, Degos L, Fenaux P; European APL Group. De Botton S, et al. Among authors: huguet f. Br J Haematol. 2000 Dec;111(3):801-6. doi: 10.1046/j.1365-2141.2000.02442.x. Br J Haematol. 2000. PMID: 11122141 Free article. Clinical Trial.
Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission.
Delannoy A, Cazin B, Thomas X, Bouabdallah R, Boiron JM, Huguet F, Straetmans N, Zérazhi H, Vernant JP, Dombret H, Bilhou-Nabera C, Charrin C, Boucheix C, Sebban C, Lhéritier V, Fière D; LALA Group, France and Belgium. Delannoy A, et al. Among authors: huguet f. Leuk Lymphoma. 2002 Jan;43(1):75-81. doi: 10.1080/10428190210180. Leuk Lymphoma. 2002. PMID: 11908739 Clinical Trial.
440 results